# Hermed Capital

> Hermed Capital is a VC fund in Shanghai backing Health Care and Biotechnology. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 8
- Last investment: Jul 2019
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/hermes-capital-partners/
- Website: http://hermescapital.com.au

Hermed Capital is a Hong Kong-based financial services company that offers related advisory services.

## Contacts

5 contacts available for Hermed Capital. Shizune tracks 1 team members at Hermed Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hermed-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 63% |
| Biotechnology | 5 | 63% |
| Health Diagnostics | 4 | 50% |
| Medical | 3 | 38% |
| Biopharma | 2 | 25% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 25% |
| Series D | 2 | 25% |
| Series A | 1 | 13% |
| Series C | 1 | 13% |
| Debt Financing | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 88% |
| China | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jerry Xiao | Managing Director | 1 | https://shizune.co/investors/profile/jerry-xiao |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hinova Pharma | Hinova Pharma is an innovative drug research and development manufacturer that provides users with compound HC-1119 androgen receptor (AR) antagonism by using drug discovery systems such as medicinal chemistry, biological screening, process research, quality research, clinical reporting, and clinical research. Drugs, HC-1102 androgen receptorinhibitors and other products, for the treatment of advanced prostate cancer and breast cancer. | $40M | Series B | Jul 31, 2019 |  |
| Prognos Health | Prognos Health is a leading health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables thequerying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers. | $20.5M | Series C | Nov 27, 2017 |  |
| Spineology | Spineology provides anatomy-conserving spine surgery technology solutions. It offers pedicular fixation products, such as Palisade, threshold, and fortress pedicular fixation; Biologics products, such as Essence viable amnion matrix, Blockade amniotic protective barrier, Incite DBM strips, and Incite cortical fibers; and Interbody products, such asthe Duo systems, Elite expandable, Rampart one, and Rampart T interbody fusion products. Spineology also offers capture facet fixation, VIA spinous process fixation, Medius retractor system, SOAR retractor system, ProMap EMG nagivation systems, and OptiMesh graft containment. Stephan Kuslich founded it in 1996, with its headquarters in St. Paul in Minnesota. | $5M | Debt Financing | Sep 13, 2017 |  |
| Whitehawk Therapeutics | Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $23M | Series A | May 08, 2017 |  |
| Epic Sciences | Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with anumber of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health. | $40M | Series D | Apr 28, 2017 |  |
| DiaMedica | DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1. | $4M | Post-IPO Equity | Jul 18, 2016 |  |
| Applied StemCell | Applied StemCell Inc. (ASC) is a fast growing biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics. Using our proprietary TARGATT™ gene modification technology, we make site-specific Knockin mouse, rat and human cell line models fast and efficient for pharmaceutical and academic community.Basedon our Proprietary Technologies, we focus on the development and commercialization of: Mouse models (Knockin, Knockout, Transgenic, Site-specific transgenic - TARGATT™, Humanized mouse models) Rat models Human cell line model (Gene modified iPSC - adult stem cell / progenitor cells - differentiated cells) Stem cell culture products (optimized stem cell medium and reporters) Gene engineering in stem cells or other mammalian cells (e.g. generation of protein - production mammalian cell lines)We are striving to improve and expand our technologies and product lines to meet the increasing requirements of biomedical community. ASC welcomes your comments, suggestions and ideas. | $19M | Series D | Jun 06, 2016 |  |
| Ativa Medical | Ativa Medical is a medical device manufacturing company that is working to make diagnostic test results available in moments, rather than hours and days. The company specializes in the fields of medical device development, point of care diagnostics, microfluidics, and hematology.The company was founded in 2008 and headquartered in Saint Paul,Minnesota. | $15M | Series B | Sep 17, 2015 |  |

8 of 8 investments shown.

## Co-investors
- [Fosun Pharma](https://shizune.co/investors/profile/fosun-pharmaceutical) — VC Fund, 2 deals together
- [Ping An Ventures](https://shizune.co/investors/profile/ping-an-ventures) — VC Fund, 2 deals together
- [Viventures](https://shizune.co/investors/profile/viventures) — VC Fund, 2 deals together
- [BioSciKin](https://shizune.co/investors/profile/bioscikin) — VC Fund, 1 deal together
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 1 deal together
- [Cigna](https://shizune.co/investors/profile/cigna) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Hermed Capital invest in?

Hermed Capital invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Series B and Series D stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Hermed Capital?

Public channels for Hermed Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Hermed Capital?

The team at Hermed Capital includes Jerry Xiao (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co